logo

For the Inventor, By the Inventor

San Diego, CA, United States of America

Elisabeth Albrecht

This inventor holds 14 USPTO granted patents, primarily in Peptide Therapeutics. Top assignees: Sibia Neurosciences, Inc., Amylin Pharmaceuticals, Inc., Amylin Corporation. Active years: 1995-2007.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Elisabeth Albrecht. Retrieved from https://idiyas.com/inventor/elisabeth-albrecht

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 14

% Patents Active = 92.9

Average Co-Inventor Count = 3.1

ph-index = 9

Forward Citations = 165(Granted Patents)


Company Filing History:

goldMedal8 out of 48 
 
Sibia Neurosciences, Inc.
 patents
silverMedal4 out of 164 
 
Amylin Pharmaceuticals, Inc.
 patents
bronzeMedal1 out of 1 
 
Amylin Corporation
 patent
4. 1 out of 834,601 
Other
 patents

Years Active: 1995-2007

Loading Chart...
Areas of Expertise:
Amylin Agonist Peptides
Neurodegenerative Disorders
Protease Inhibitors
Peptide Analog
Amino Acid Analog
Synthetic Preparation
Amylin Antagonist Peptides
Compositions
Pharmaceutical Applications
Therapeutic Uses
Peptide Chemistry
Biological Activity
14 patents (USPTO):Explore Patents
1. 7271238 - Amylin agonist peptides and uses therefor (2007-09-18),
2. 6610824 - Amylin agonist peptides and uses therefor (2003-08-26),
3. 6051684 - Methods of treating neurodegenerative disorders using protease inhibitors (2000-04-18),
4. 6017887 - Peptide, peptide analog and amino acid analog protease inhibitors (2000-01-25),
5. 6015879 - Peptide and peptide analog protease inhibitors (2000-01-18),
6. 5998367 - Pramlintide pro H-amylin salts and compositions (1999-12-07),
7. 5969100 - Peptide, peptide analog and amino acid analog protease inhibitors (1999-10-19),
8. 5962419 - Peptide and peptide analog protease inhibitors (1999-10-05),
9. 5872101 - Methods of treating neurodegenerative disorders using protease inhibitors (1999-02-16),
10. 5863902 - Methods of treating neurodegenerative disorders using protease inhibitors (1999-01-26),
11. 5804560 - Peptide and peptide analog protease inhibitors (1998-09-08),
12. 5686411 - Amylin agonist peptides and uses therefor (1997-11-11),
13. 5580953 - Amylin antagonist peptides and uses therefor (1996-12-03),
14. 5424394 - Synthetic preparation of amylin and amylin analogues (1995-06-13),

Title: The Innovative Contributions of Elisabeth Albrecht

Introduction

Elisabeth Albrecht is a prominent inventor based in San Diego, CA. She has made significant contributions to the field of pharmaceuticals, particularly in the treatment of diabetes and related conditions. With a total of 14 patents to her name, her work has had a profound impact on medical science.

Latest Patents

Among her latest patents are groundbreaking developments in amylin agonist peptides. These patents include agonist analogues of amylin and related pharmaceutical compositions, which provide methods for treating diabetes and other insulin-requiring states. Additionally, her work addresses methods for treating hypoglycemia, showcasing her commitment to advancing healthcare solutions.

Career Highlights

Elisabeth has worked with notable companies such as Sibia Neurosciences, Inc. and Amylin Pharmaceuticals, Inc. Her experience in these organizations has allowed her to collaborate with leading experts in the field, further enhancing her innovative capabilities.

Collaborations

Some of her notable coworkers include Ian A McDonald and Benito Munoz. Their collaborative efforts have contributed to the success of her projects and the advancement of medical treatments.

Conclusion

Elisabeth Albrecht's contributions to the field of pharmaceuticals through her innovative patents and collaborations highlight her as a key figure in medical research. Her work continues to influence the treatment of diabetes and related conditions, making a lasting impact on healthcare.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…